HMOX1 and asthma: We identified HMOX1, ITGAM, SFTPD and ADAM17 as the top novel targets for asthma which need to be validated experimentally whereas IL-18, TNF and VEGFA as the strongest therapeutic targets to investigate further for clinical benefit.